Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers

Abstract excerpt

genes result in the elevation of cellular active RAS protein levels and increased signal propagation through downstream pathways that drive tumor cell proliferation and survival. These gain-of-function mutations drive over 30% of all human cancers, presenting promising therapeutic potential for RAS inhibitors. However, many have deemed RAS "undruggable" after nearly 40 years of failed drug discovery campaigns...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Click Chemistry and Applications
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to RNA Interference and Gene Delivery